TY - JOUR
T1 - Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome
AU - Schramm, Elizabeth C.
AU - Roumenina, Lubka T.
AU - Rybkine, Tania
AU - Chauvet, Sophie
AU - Vieira-Martins, Paula
AU - Hue, Christophe
AU - Maga, Tara
AU - Valoti, Elisabetta
AU - Wilson, Valerie
AU - Jokiranta, Sakari
AU - Smith, Richard J.H.
AU - Noris, Marina
AU - Goodship, Tim
AU - Atkinson, John P.
AU - Fremeaux-Bacchi, Veronique
N1 - Publisher Copyright:
© 2015 by The American Society of Hematology.
PY - 2015/4/9
Y1 - 2015/4/9
N2 - The pathogenesis of atypical hemolytic uremic syndrome (aHUS) is strongly linked to dysregulation of the alternative pathway of the complement system. Mutations in complement genes have been identified in about two-thirds of cases, with 5% to 15% being in C3. In this study, 23 a HUS-associated genetic changes in C3 were characterized relative to their interaction with the control proteins factor H (FH), membrane cofactor protein (MCP; CD46), and complement receptor 1 (CR1; CD35). In surface plasmon resonance experiments, 17 mutant recombinant proteins demonstrated a defect in binding to FH and/or MCP, whereas 2 demonstrated reduced binding to CR1. In the majority of cases, decreased binding affinity translated to a decrease in proteolytic inactivation (known as cofactor activity) of C3b via FH and MCP. These results were used to map the putative binding regions of C3b involved in the interaction with MCP and CR1 and interrogated relative to known FH binding sites. Seventy-six percent of patients with C3 mutations had low C3 levels that correlated with disease severity. This study expands our knowledge of the functional consequences of aHUS-associated C3 mutations relative to the interaction of C3 with complement regulatory proteins mediating cofactor activity.
AB - The pathogenesis of atypical hemolytic uremic syndrome (aHUS) is strongly linked to dysregulation of the alternative pathway of the complement system. Mutations in complement genes have been identified in about two-thirds of cases, with 5% to 15% being in C3. In this study, 23 a HUS-associated genetic changes in C3 were characterized relative to their interaction with the control proteins factor H (FH), membrane cofactor protein (MCP; CD46), and complement receptor 1 (CR1; CD35). In surface plasmon resonance experiments, 17 mutant recombinant proteins demonstrated a defect in binding to FH and/or MCP, whereas 2 demonstrated reduced binding to CR1. In the majority of cases, decreased binding affinity translated to a decrease in proteolytic inactivation (known as cofactor activity) of C3b via FH and MCP. These results were used to map the putative binding regions of C3b involved in the interaction with MCP and CR1 and interrogated relative to known FH binding sites. Seventy-six percent of patients with C3 mutations had low C3 levels that correlated with disease severity. This study expands our knowledge of the functional consequences of aHUS-associated C3 mutations relative to the interaction of C3 with complement regulatory proteins mediating cofactor activity.
UR - http://www.scopus.com/inward/record.url?scp=84927526565&partnerID=8YFLogxK
U2 - 10.1182/blood-2014-10-609073
DO - 10.1182/blood-2014-10-609073
M3 - Article
C2 - 25608561
AN - SCOPUS:84927526565
SN - 0006-4971
VL - 125
SP - 2359
EP - 2369
JO - Blood
JF - Blood
IS - 15
ER -